anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== External links == WHO: Good Distribution Practices (GDP) for Pharmaceutical Products Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03) Counterfeit Drugs (FDA) Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (FDA) GDP Guidelines of 7 March 2013 (Eudralex) Guidelines on Good Distribution Practice (NPCB/Malaysia) GDP Guidelines of 7 March 2013 (Eudralex) How to become pharmaceutical distributor
==== Mount Koya ==== It was developed by Mokujiki Shonin, a Shingon priest in the early 1600s during the Edo Period. He encouraged all the mountain temples to make their own tofu after he obtained large amounts of soybeans from the head Shingon temple. The purpose of this was to preserve some of the frozen tofu until the Spring equinox. Firm tofu was left outdoors in the cold windy night to freeze. After it was frozen, it was allowed to stand on shelves in a shed for fifteen days at temperatures below freezing, thawed in warm water and pressed lightly to expel the melted ice, then dried in the shed using heat from charcoal braziers.
The former maintains its own border control policies, thus requiring physical border security at its border with the Schengen Area, as well as implementing border controls for travellers travelling directly between Gibraltar and the British mainland. The latter maintains a relatively open border with Southern Cyprus, though not with Northern Cyprus. Consequently, it is a de facto member of the Schengen Area, and travel to or from the British mainland is subject to border controls. On 31 December 2020, Spain and the United Kingdom reached an agreement in principle under which Gibraltar would join the Schengen Area, clearing the way for the European Union and the UK to start formal negotiations on the matter. In the aftermath of Brexit, border controls for goods flowing between Great Britain and Northern Ireland were introduced in accordance with the Protocol on Ireland/Northern Ireland agreed to as part of the UK's withdrawal agreement with the EU. Due to the thirty-year internecine conflict in Northern Ireland, the UK-Ireland border has had a special status since that conflict was ended by the Belfast Agreement/Good Friday Agreement of 1998. As part of the Northern Ireland Peace Process, the border has been largely invisible, without any physical barrier or custom checks on its many crossing points; this arrangement was made possible by both countries' common membership of both the EU's Single Market and Customs Union and of their Common Travel Area.
passive transport The movement of a solute across a membrane by traveling down an electrochemical or concentration gradient, using only the energy stored in the gradient and not any energy from external sources. Contrast active transport.
Sources: en.wikipedia.org
=== 16 May === Two people were killed in Russian attacks in Kharkiv Oblast. One person was killed in a separate attack in Kherson Oblast. Ukrainian media reported that the HUR launched a drone attack on a weapons manufacturing plant in Russia's Tula Oblast. President Zelenskyy arrived in Kharkiv to meet with the military leadership, saying that the situation in Kharkiv Oblast was "generally under control" but the area remained "extremely difficult". A police official in Kharkiv said that up to 40 civilians in Vovchansk who attempted to flee shelling were captured by Russian forces and were reportedly imprisoned in basements where they are interrogated by alleged FSB agents. According to Ukrainian Interior Minister Ihor Klymenko, Russian soldiers in Vovchansk executed a civilian prisoner after he refused to obey orders and attempted to flee. Police opened a criminal investigation on the grounds of violations of laws of war. Ukrainian soldiers in the Kharkiv front reported that they had "never seen anything close to the number of Lancets (drones) flying" compared to earlier battles. The ISW assessed that the "tempo of Russian offensive operations in the area continues to decrease".
In Hong Kong, the accrediting body is Hong Kong Accreditation Service (HKAS). On 16 February 2004, HKAS launched its medical testing accreditation programme. In Canada, laboratory accreditation is not mandatory, but is becoming more and more popular. Accreditation Canada (AC) is the national reference. Different provincial oversight bodies mandate laboratories in EQA participations like LSPQ (Quebec), IQMH (Ontario) for example.
=== Neonatal abstinence === Buprenorphine has been used in the treatment of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application. Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.
Matrine is an alkaloid found in plants from the family Fabaceae. It has a variety of pharmacological effects, including in-vitro anti-cancer effects, as well as κ-opioid and μ-opioid receptor agonism. Matrine possesses strong antitumor activities in vitro and in vivo. Inhibition of cell proliferation and induction of apoptosis are the likely mechanisms responsible for matrine's antitumor activities. Matrine can be commercially extracted from the traditional Chinese medical herb Sophora flavescens Ait. Mu opioid agonism is associated with euphoria, while kappa opioid agonism is associated with dysphoria and psychotomimetic hallucinations (as seen in the kappa-agonist Salvinorin A). Both receptors are known to produce analgesia when activated. Matrine and the related compound oxymatrine have a toxic effect against the formosan subterranean termite. Additionally, it acts as a nematicide against the pine wood nematode which causes pine wilt, as well as pathogenic nematodes which target humans. Matrine alleviates neuro-inflammation and oxidative stress in the brain caused by acute liver injury, thus producing antianxiety and antidepression effects.
The Chinese government has introduced a number of "fat farms" where obese children go for reinforced exercise and has passed a law which requires students to exercise or play sports for an hour a day at school (see Obesity in China). In a structured setting with a trained therapist, these interventions produce an average weight loss of up to 8 kg in 6 months to 1 year, and 67% of people who lost greater than 10% of their body mass maintained or continued to lose weight one year later. There is a gradual weight regain after the first year of about 1 to 2 kg per year, but on the long-term this still results in weight loss. Risk factors for cardiovascular disease and for diabetes are reduced for several years after taking part in a weight management programme, even if people regained weight. Attending group meetings for weight reduction programmes rather than receiving one-on-one support may increase the likelihood that obese people will lose weight. Those who participated in groups had more treatment time and were more likely to lose enough weight to improve their health. Study authors suggested that one explanation for the difference is that group participants spent more time with the clinician (or whoever delivered the programme) than those receiving one-on-one support. Comprehensive diet programs, providing counseling, targets for calorie intake and exercise, may be more efficient than dieting without guidance ("self-help"), although the evidence is very limited.
Sources: en.wikipedia.org
== Awards and honors == Member of the National Academy of Sciences (1976) Fellow of the American Academy of Arts and Sciences (1975) Gairdner Foundation International Award (1975) Member of the Institute of Medicine (2004) Beutler was a president of both the American Society of Hematology and the Western Association of Physicians. He also received a Doctor Philosophiae Honoris Causa, Tel Aviv University. He was also elected to the United States National Academy of Sciences and was presented with the inaugural Award for Lifetime Achievement from The American Society of Hematology. He was a recipient of the American Society of Hematology's E. Donnall Thomas Prize in 2003.
== Function == In eubacteria, there are three groups of factors that promote protein synthesis: initiation factors, elongation factors and termination factors. The elongation phase of translation is promoted by three universal elongation factors, EF-Tu, EF-Ts, and EF-G. EF-P was discovered in 1975 by Glick and Ganoza, as a factor that increased the yield of peptide bond formation between initiator fMet-tRNA(fMet) and a mimic of aa-tRNA, puromycin (Pmn). The low yield of product formation in absence of EF-P can be described by the loss of peptidyl-tRNA from the stalled ribosome. Thus, EF-P is not a necessary component of minimal in vitro translation system, however, the absence of EF-P can limit translation rate, increase antibiotic sensitivity, and slow growth. To complete its function, EF-P enters paused ribosomes through the E-site and facilitates peptide bond formation through interactions with the P-site tRNA. EF-P and eIF-5A both are essential for the synthesis of a subset of proteins containing proline stretches in all cells. It has been suggested that after binding of the initiator tRNA to the P/I site, it is correctly positioned to the P site by binding of EF-P to the E site. Additionally, EF-P has been shown to assist in efficient translation of three or more consecutive proline residues.
Silver bromide is used, either alone or in combination with silver chloride and silver iodide, as the light sensitive constituent of photographic emulsions. Ethylene bromide was an additive in gasolines containing lead anti-engine knocking agents. It scavenges lead by forming volatile lead bromide, which is exhausted from the engine. This application accounted for 77% of the bromine use in 1966 in the US. This application has declined since the 1970s due to environmental regulations (see below). Vegetable oil modified by bromine known as Brominated vegetable oil (BVO), was used since the 1920s, to primarily help emulsify citrus-flavoured soft drinks, preventing them from separating during distribution. In 2024, the FDA banned the use of BVO in food. Poisonous bromomethane was widely used as pesticide to fumigate soil and to fumigate housing, by the tenting method. Ethylene bromide was similarly used. These volatile organobromine compounds are all now regulated as ozone depletion agents. The Montreal Protocol on Substances that Deplete the Ozone Layer scheduled the phase out for the ozone depleting chemical by 2005, and organobromide pesticides are no longer used (in housing fumigation they have been replaced by such compounds as sulfuryl fluoride, which contain neither the chlorine or bromine organics which harm ozone). Before the Montreal protocol in 1991 (for example) an estimated 35,000 tonnes of the chemical were used to control nematodes, fungi, weeds and other soil-borne diseases.
Quaternary structure is the three-dimensional structure consisting of the aggregation of two or more individual polypeptide chains (subunits) that operate as a single functional unit (multimer). The resulting multimer is stabilized by the same non-covalent interactions and disulfide bonds as in tertiary structure. There are many possible quaternary structure organisations. Complexes of two or more polypeptides (i.e. multiple subunits) are called multimers. Specifically it would be called a dimer if it contains two subunits, a trimer if it contains three subunits, a tetramer if it contains four subunits, and a pentamer if it contains five subunits, and so forth. The subunits are frequently related to one another by symmetry operations, such as a 2-fold axis in a dimer. Multimers made up of identical subunits are referred to with a prefix of "homo-" and those made up of different subunits are referred to with a prefix of "hetero-", for example, a heterotetramer, such as the two alpha and two beta chains of hemoglobin.
While disembarking her train, she loses contact with the Caller, realizing her phone has been pickpocketed. Maia races the train to the next station and confronts the thief, threatening him with her gun, which attracts the attention of police and forces her to escape through an Underground tunnel. When she exits the Underground, she is confronted by police searching for her but escapes by hiding in a nearby church. Maia re-establishes contact with the Caller, who now plans to kill Tafa himself with a bomb. She tells him that she was the one who murdered her father, using a pistol she used for target shooting. The Caller gives her 15 minutes to get to the hotel and shoot Tafa. After being recognized by a police officer while crossing Waterloo Bridge, she leaps off the bridge onto a passing barge, then jumps from the ship onto a jetty near the HMS Belfast. She arrives at the hotel and heads to Tafa's 53rd-floor suite, where she shoots him several times as the Caller watches. The Caller, who is several floors above at the hotel, pulls a fire alarm and departs. Maia reaches Noah and gives him a dose of glucagon to revive him. In the lobby, Maia is met by a police detective, who informs her that the Caller is still nearby but does not arrest her. Noah spots the Caller through a window, disguised as a paramedic, but Maia cannot reach him as the hotel is locked down. He smugly confronts her, only to notice a still-living Tafa being escorted out by police.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.